Last updated on April 19, 2014 at 1:20 EDT

Inspiration Biopharmaceuticals to Present at the UBS Global Life Sciences Conference

September 13, 2012

CAMBRIDGE, Mass., Sept. 13, 2012 /PRNewswire/ — Inspiration Biopharmaceuticals, Inc., an emerging biopharmaceutical company developing new treatment options for people with hemophilia, today announced that John P. Butler, Chief Executive Officer, will present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012. The presentation will take place at 4:00 p.m. ET at the Grand Hyatt Hotel in New York.

About Inspiration Biopharmaceuticals
As the only biopharmaceutical company dedicated solely to hemophilia, Inspiration is committed to improving the care of people with this condition by broadening treatment choices, expanding global access to care and advancing innovative therapies. Founded by two families whose sons have hemophilia, Inspiration is inspired to make a difference in the lives of people impacted by hemophilia around the world. Inspiration’s lead product candidates are IB1001, an investigational intravenous recombinant factor IX being developed for the treatment of hemophilia B, and OBI-1, an investigational recombinant porcine factor VIII being developed for the treatment of serious bleeds in patients with congenital hemophilia A with inhibitors or acquired hemophilia A.

For more information about Inspiration Biopharmaceuticals, please visit www.inspirationbio.com.


    Media                          Investors
    Kate Lewis                     Gordon H. Busenbark
    Feinstein Kean Healthcare       Senior Vice President, Chief
                                    Financial Officer
    Tel: +1-617-577-8110           Tel: +1-617-588-1802
    Email: kate.lewis@fkhealth.com

SOURCE Inspiration Biopharmaceuticals, Inc.

Source: PR Newswire